PRLD stock forecast, quote, news & analysis
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients... Show more
Why Prelude Therapeutics (PRLD) Stock Is Down -27% in the Last 30 Days
Key Takeaways
- PRLD shares have declined roughly 27% over the last 30 days, from a closing price near $4.87 to approximately $3.55.
- The pullback occurred despite several positive developments, including FDA clearance of the PRT13722 IND, a clinical supply agreement with Eli Lilly (LLY), and multiple analyst initiations and reiterations.
- Rising short interest and profit-taking after a strong prior run-up contributed to selling pressure.
- Over the trailing quarter, the stock was volatile, rallying to a multi-month high near $6.50 in late August before retracing.
- Key forward catalysts include Phase 1 execution for PRT12396 and PRT13722 and Incyte's (INCY) option decision.
Prelude Therapeutics (PRLD) Company Overview and Market Position
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on developing medicines for cancers with high unmet need. The company's pipeline is anchored by two differentiated programs: PRT12396, a mutant-selective JAK2V617F inhibitor designed to target the primary driver mutation in myeloproliferative neoplasms such as polycythemia vera and myelofibrosis, and PRT13722, a first-in-class, highly selective oral KAT6A degrader being developed for hormone-receptor-positive, HER2-negative breast cancer.
Beyond its lead assets, Prelude leverages its targeted protein degradation expertise to develop next-generation degrader antibody conjugates, or DACs, through a collaboration with AbCellera (ABCL). Investors follow the stock for its binary, milestone-driven pipeline catalysts rather than near-term revenue, making it a higher-volatility, event-sensitive biotech holding.
Prelude Therapeutics (PRLD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PRLD fell approximately 27%, sliding from a close of $4.87 on September 18 to about $3.55 at the latest available quote. The move was largely one-directional, with the stock grinding lower through late September and early October despite intermittent bounces.
The trailing quarter tells a more volatile story. The shares climbed from roughly $4 in mid-July to a multi-month peak near $6.50 in late August, supported by second-quarter results and pipeline momentum, before giving back those gains and ending around $3.55 — a decline of roughly 13% from the mid-July level. In other words, the recent 30-day slide represents a sharp unwinding of the prior quarterly rally.
What Drove PRLD Stock Price in the Last 30 Days
The last 30 days featured a series of fundamentally supportive headlines. On September 10, the FDA cleared Prelude's IND for PRT13722, enabling a Phase 1 study in HR+/HER2- breast cancer with enrollment anticipated in the fourth quarter. In mid-September, JPMorgan initiated coverage with an Overweight rating and a $12 price target, citing the potential of PRT12396. In October, Prelude announced a clinical trial collaboration and supply agreement with Eli Lilly for abemaciclib and imlunestrant, prompting H.C. Wainwright to reiterate a Buy rating with an $8 target and Citigroup to reiterate a Market Outperform rating.
Despite these catalysts, the stock declined. Verified market data shows short interest rose approximately 26% between the mid-September and late-September settlements, to roughly 4.6 million shares, indicating increased bearish positioning. The retreat also coincided with profit-taking after a dramatic multi-month advance and broader pressure on small-cap and clinical-stage biotech names, underscoring that positive news flow does not always translate into immediate share-price gains.
What Drove PRLD Stock Performance Over the Last Quarter
The broader three-month trend was defined by a strong rally followed by a sharp retracement. On August 11, Prelude reported second-quarter 2026 results showing a narrowed net loss and a strengthened balance sheet, with $155.2 million in cash expected to fund operations into the second quarter of 2028. Management also highlighted progress across the pipeline, and the shares surged toward $6.50 in late August.
Momentum was further supported by the initiation of the PRT12396 Phase 1 study and the PRT13722 IND clearance. However, as the quarter progressed, the rally cooled. A lack of near-term clinical data readouts, elevated short interest, and a risk-off tilt in the biotech sector weighed on the stock, leaving it lower over the period despite the constructive fundamental backdrop.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's top-performing artificial-intelligence trading bots. While Tickeron offers hundreds of AI trading bots that monitor and trade thousands of tickers, only the most relevant and highest-performing bots are featured in this dedicated section. The bots vary widely in strategy, holding timeframe, and performance metrics, allowing traders to browse approaches aligned with different risk profiles and objectives. Because the selection is continually updated to reflect current performance, the page serves as a useful starting point for those evaluating systematic, data-driven trading strategies. Explore the Trending AI Robots page to review the latest featured bots and their track records.
PRLD Stock Forecast Drivers: What Investors Should Watch Next
Investors will be watching execution on both lead programs. The Phase 1 study of PRT12396 in polycythemia vera and myelofibrosis is enrolling, and the Phase 1 trial of PRT13722 in HR+/HER2- breast cancer is expected to begin enrolling patients in the fourth quarter. Near-term catalysts also include quarterly earnings and any update on the Incyte option agreement, which management has indicated could provide substantial non-dilutive financing if exercised. Broader factors, including small-cap biotech sentiment, short interest dynamics, and the pace of clinical enrollment, will also influence the stock's path. These are high-risk, milestone-dependent catalysts, and outcomes remain uncertain.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PRLD's RSI Oscillator climbs out of oversold territory
The RSI Indicator for PRLD moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 26 of the 28 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 66 cases where PRLD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for PRLD just turned positive on October 20, 2026. Looking at past instances where PRLD's MACD turned positive, the stock continued to rise in 45 of 50 cases over the following month. The odds of a continued upward trend are 90%.
Following a +7.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRLD advanced for three days, in 229 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
PRLD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRLD as a result. In 86 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The 10-day moving average for PRLD crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRLD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for PRLD entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.148) is normal, around the industry mean (2.988). P/E Ratio (-4.932) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (16.779) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PRLD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology